Contineum Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Contineum Therapeutics, Inc. (CTNM) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2025-03-06
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-09-30 was 0.00 shares.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2024-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-09-30 was 0.00 shares.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2023-06-30 was 1.75K shares.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of call options and warrants for fiscal 2023 was 1.70K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 12 month |
|---|---|---|---|---|
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-06 | |||
| 2024-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 0.00 shares 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | 0.00 shares 10-Q · filed 2024-08-14 | 0.00 shares 10-Q · filed 2024-08-14 | ||
| 2023-12-31 | 1.70K shares 10-K · filed 2025-03-06 | |||
| 2023-09-30 | 0.00 shares 10-Q · filed 2024-11-06 | 1.75K shares 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | 1.75K shares 10-Q · filed 2024-08-14 | 1.58K shares 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |